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N-methyl-D-aspartate receptors (NMDARs) are ligand-gated ion channels (‘ionotropic’ receptors) acti-
vated by the major excitatory neurotransmitter, L-glutamate. While the term ‘the NMDAR’ is often used it
obscures the fact that this class of receptor contains within it members whose properties are as different
as they are similar. This heterogeneity was evident from early electrophysiological, pharmacological and
biochemical assessments of the functional properties of NMDARs and while the molecular basis of this
heterogeneity has taken many years to elucidate, it indicated from the outset that the diversity of
NMDAR phenotypes could allow this receptor family to subserve a variety of functions in the mammalian
central nervous system. In this review we highlight some recent studies that have identiﬁed structural
elements within GluN2 subunits that contribute to the heterogeneous biophysical properties of NMDARs,
consider why some recently described novel pharmacological tools may permit better identiﬁcation of
native NMDAR subtypes, examine the evidence that NMDAR subtypes differentially contribute to the
induction of long-term potentiation and long-term depression and discuss how through the use of
chimeric proteins additional insights have been obtained that account for NMDAR subtype-dependency
of physiological and pathophysiological signalling.
This article is part of the Special Issue entitled ‘Glutamate Receptor-Dependent Synaptic Plasticity’.
 2013 Elsevier Ltd.Open access under CC BY license.1. Introduction
N-methyl-D-aspartate receptors (NMDARs) are a subclass of
ionotropic glutamate receptors (iGluRs) that play pivotal physio-
logical and pathophysiological roles in the mammalian central
nervous system (CNS), the majority of which are tetrameric as-
semblies of two GluN1 and two GluN2 subunits (for recent reviews
see Paoletti (2011), Traynelis et al. (2010)). Classically, glutamate-
mediated NMDAR activity, as opposed to AMPA/kainate or metab-
otropic activity, is identiﬁed pharmacologically by its sensitivity to
the selective antagonists such a 2-amino-5-phosphonopentanoic
acid (AP5; Davies and Watkins, 1982; Evans et al., 1982) or MK-
801 (Wong et al., 1986). Uniquely among iGluRs, NMDARs require
binding of two different agonists e glutamate and glycine (or D-
serine) for their activation. The obligate GluN1 subunit harbours
the co-agonist glycine (D-serine) binding site and, although being
encoded by a single gene, can exist in eight, spatially and tempo-
rally regulated, isoforms (GluN1-1a to GluN1-4a, and, GluN1-1b to
GluN1-4b) which arise from the alternative RNA splicing of exons 5,
21 and 22 (Laurie and Seeburg, 1994; Sugihara et al., 1992). Four
types of GluN2 subunits exist (AeD) and are encoded by fourx: þ44 131 650 2872.
. Wyllie).
 license.separate genes. GluN2 subunits contain the glutamate-binding site
(Anson et al., 1998; Laube et al., 1997) and display a devel-
opmentally and spatially regulated expression pattern (Monyer
et al., 1994; Watanabe et al., 1992). In rodents, GluN2B expression
is prominent during embryonic and early post-natal development
and remains high in the adult brain. Strong GluN2A expression
begins around the second post-natal week of development and
together with GluN2B subunits these are the predominantly
expressed NMDAR subunits in the adult forebrain. Expression of
GluN2C and GluN2D subunits is considerably more restricted e
GluN2C is expressed highly, albeit not exclusively in the cere-
bellum, whereas GluN2D expression is highest during early
development in the diencephalon, cerebellum and brain stem
although, as discussed below, functional GluN2D-containing
NMDARs are present at older ages, particularly in the basal ganglia.
The speciﬁc sub-cellular localisation of GluN2A and GluN2B-
containing NMDARs within the adult forebrain has been of consid-
erable interest given the differing roles of synaptic and extrasynaptic
NMDARs in signalling to neuronal survival and death (reviewed in
Hardingham and Bading, 2010). The often-stated notion that
GluN2A-containing and GluN2B-containing NMDARs are predomi-
nately localised at synaptic and extra-synaptic sites, respectively, is
an oversimpliﬁcation. There is evidence that GluN2B-containing
NMDARs are enriched at extrasynaptic sites (Groc et al., 2006;
Martel et al., 2009b; Tovar and Westbrook, 1999) but this is not to
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GluN2A expression is high (Gray et al., 2011; Harris and Pettit, 2007;
Rauner and Kohr, 2011; Thomas et al., 2006; Tovar et al., 2009).
As summarised in Fig.1, the identity of the GluN2 subunit within
a di-heteromeric complex endows NMDARs with a unique set of
pharmacological biophysical properties (Paoletti, 2011; Traynelis
et al., 2010). Brieﬂy, GluN1/GluN2A and GluN1/GluN2B NMDARs
display a higher sensitivity to voltage-dependent Mg2þ block,
higher Ca2þ permeability and higher single-channel conductance
than their GluN1/GluN2C and GluN1/GluN2D counterparts (Kuner
and Schoepfer, 1996; Schneggenburger, 1996; Stern et al., 1992;
Wyllie et al., 1996). The potencies of glutamate, NMDA and other
related agonist analogues are dependent on the form of the GluN2
subunit (Erreger et al., 2007), which also exerts indirect control
over potency for agonists acting at the GluN1 glycine/D-serine
binding site (Chen et al., 2008). Furthermore, the nature of the
GluN2 subunit also largely determines the deactivation proﬁle of the
response to brief applications of agonist, as occurs during synaptic
transmission (Monyer et al., 1992; Vicini et al., 1998; Wyllie et al.,
1998). For each of these sets of biophysical properties considerable
insights have been made recently which highlight how these
subtype-dependent parameters are controlled and regulated.
In addition to GluN2 regulation of NMDAR function, a third type
of subunit, GluN3 (Chatterton et al., 2002; Ciabarra et al., 1995; Das
et al., 1998; Sucher et al., 1995) can also be incorporated into
NMDARs and which results in a modiﬁcation of their properties.
Moreover expression of only GluN1 and GluN3 subunits forms
a glycine-gated excitatory receptor. Our understanding of the
physiological roles for GluN3-containing NMDARs is considerably
less advanced than that for ‘classical’ GluN1-GluN2 NMDARs
(Pachernegg et al., 2012) and is beyond the scope of this review,
which will focus on the pivotal role GluN2 subunits play in deter-
mining the functional properties of NMDARs.Fig. 1. The identity of the GluN2 subunit controls pharmacological and biophysical propert
with the GluN1 subunits indicated in grey. Agonist and co-agonist potency is lowest at Gl
fastest for GluN2A-containing NMDARs and slowest for NMDARs containing GluN2D subuni
rates. NMDARs fall into two categories (GluN2A/B-like and GluN2C/D-like) when considerin2. Structure of NMDARs
Structural knowledge of vertebrate iGluRs has been funda-
mentally advanced in recent years by a number of X-ray crys-
tallography studies that describe atomic resolution structures
(Kumar and Mayer, 2012). For NMDARs, this includes crystal
structures of isolated amino terminal domain (ATD) and ligand-
binding domain (LBD) from GluN1 and GluN2 subunits (Farina
et al., 2011; Furukawa and Gouaux, 2003; Furukawa et al., 2005;
Inanobe et al., 2005; Karakas et al., 2009, 2011), however no com-
plete NMDAR structure has been described to date and therefore
the X-ray structure of a closely-related homomeric GluA2 AMPAR
provides an invaluable structural surrogate to develop NMDAR
models (Sobolevsky et al., 2009). The emerging view of the NMDAR
indicates an intricate and domain-speciﬁc complexity (Fig. 2).
Initial studies into the quaternary structure of NMDARs pro-
posed a ‘non-alternate’ subunit arrangement (GluN1/GluN1/GluN2/
GluN2; Schorge and Colquhoun, 2003), however, experimental
evidence from cysteine-linking studies points to an alternating
(GluN1/GluN2/GluN1/GluN2) subunit arrangement (Lee and
Gouaux, 2011; Riou et al., 2012; Salussolia and Wollmuth, 2012;
Sobolevsky et al., 2009) which is further supported by the co-
crystallization of GluN1 and GluN2A ATDs in a ‘hetero-dimer’
arrangement (Furukawa et al., 2005).
NMDAR ATD crystals show a bilobar structure comprised of an
upper R1 and lower R2 lobe which are formed from the ﬁrst
approximately 380 amino acids of the protein (Farina et al., 2011;
Karakas et al., 2009, 2011; Stroebel et al., 2011). Importantly, the
NMDAR ATD have very little sequence homology with other iGluR
ATDs and notable differences are present between crystal struc-
tures of AMPAR and NMDAR ATDs (Furukawa, 2012), the major
being the relative position of the R1 and R2 lobes which are twisted
by 40e50 with respect to their AMPAR counterparts (Karakasies of NMDARs. Schematic representation of each of the four di-heteromeric NMDARs
uN1/GluN2A NMDARs and highest at GluN1/GluN2D NMDARs. Deactivation rates are
ts. GluN2B- and GluN2C-containing NMDARs show approximately similar deactivation
g voltage-dependent block by Mg2þ, permeability to Ca2þ and unitary conductance.
Fig. 2. Structure of ionotropic glutamate receptors. (a) Upper panel, linear representation of iGluR subunit highlighting the four functional domains; lower panel, schematic of the
general structure of an iGluR subunit indicating the extracellularly located amino terminal domain (ATD) and ligand-binding domain (LBD) the transmembrane domain (TMD)
comprised of three membrane-spanning helices (M1, M3 and M4) together with the re-entrant P-loop region of M2 and the large intracellularly located C-terminal domain (CTD).
(b) Ribbon structure representation of the rat GluA2 homomeric AMPAR with each of the four subunits coloured coded and indicating the two conformationally distinct pairs of
subunits, A/C and B/D. (c) model of the overall architecture of the NMDAR based on the GluA2 crystal structures of the ATD and TMD and the GluN1-GluN2A LBD heterodimer crystal
structure. Panels (b) and (c) adapted from Sobolevsky et al. (2009). Copyright  2009 Nature Publishing Group. Used with permission.
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binding sites for a number of ligands such as ifenprodil (and related
compounds), protons and Zn2þ (Karakas et al., 2009, 2011;
Furukawa, 2012). The GluN2B ATD crystal structure reveals the
Zn2þ binding site to be within the cleft created by the R1 and R2
lobes (Karakas et al., 2009). Conversely, allosteric ligands, such as
ifenprodil and Ro25-6981 bind at the dimer interface of GluN1 and
GluN2B subunits (Karakas et al., 2011).
The LBD is highly conserved in all GluN2 subunits; indeed, the
near equal sequence identity of the glutamate binding site (Chen
and Wyllie, 2006) has meant the development of GluN2-selective
competitive antagonists has, so far, been largely unrewarding (see
below). X-ray crystallography studies of the LBD have been per-
formed with various agonists and competitive antagonists and
demonstrate the recognition site is composed of two discontinuous
lobes, D1 and D2, also arranged in a bilobar structure (Furukawa
and Gouaux, 2003; Furukawa et al., 2005; Inanobe et al., 2005).
The D1 region is largely formed from the S1 sequence stretching
from the ATD to the start of the ﬁrst transmembrane domain (M1),
while the D2 region is mainly formed by the S2 region located
between M3-M4. The crystal structure of the homomeric AMPAR
(Fig. 2b) depicts a ‘dimer of dimers’ arrangement at the LBD,
however two different subunit conformations exist referred to as A/
C and B/D pairs (Sobolevsky et al., 2009). For NMDARs, assuming
the ‘alternating’ arrangement GluN1 and GluN2 subunits the A/C
pairs would be comprised of GluN1 subunits while B/D pairs would
be GluN2 (Sobolevsky et al., 2009).
The transmembrane domain (TMD) represents the most highly
conserved portion of NMDAR subunits and consists of three
transmembrane helical segments (M1, M3 and M4) with an addi-
tional a short re-entrant ‘P’-loop (M2) between the M1 and M3
segments. The crystal structure of the closed AMPAR poredemonstrates that the M3 helices interact close to the iGluR-
conserved ‘SYTANLAAF’ motif at the extracellular side of the
membrane to form a constriction that forms the channel gate
(Sobolevsky et al., 2009). For the open channel conﬁguration,
substituted cysteine accessibility studies (Beck et al., 1999; Kuner
et al., 1996) indicate that speciﬁc portions of the M1, M3 and M4
helices contribute to form a large extracellular vestibule located
above the central M2 segment, which forms the narrowest part of
the channel. The directly channel-facing apex of the M2 loop in
iGluRs harbours the Q/R/N site and creates a major rate-limiting
determinant of single-channel conductance, Ca2þ permeation and
voltage-dependent Mg2þ block (Burnashev et al., 1992; Mori et al.,
1992; Sakurada et al., 1993; Wollmuth et al., 1998).
The large (>600 amino acids in the GluN2A and GluN2B)
intracellularly located CTD is least conserved between GluN2 (Ryan
et al., 2008; Traynelis et al., 2010). The CTD contains speciﬁc
binding motifs for intracellular trafﬁcking and signalling proteins,
scaffold proteins and several phosphorylation sites (Lau and Zukin,
2007; Salter and Kalia, 2004). No direct structural information is
available for the NMDAR CTD, but is predicted to have a number of
a-helical structures as assessed using a bioinformatical approach
(Ryan et al., 2008).
3. Biophysical properties of NMDAR subtypes
As stated above the NMDARs fall into two distinct classes when
considering their sensitivity to voltage-dependent block by
extracellular Mg2þ, their permeability to Ca2þ and their single-
channel conductance (Wyllie and Traynelis, 2012). It has been
known for many years that each of these properties is considerably
affected by mutations of asparagine residues located at the Q/R/N
site located near the apex of the M2 re-entrant loop of both GluN1
Fig. 3. The Ser/Leu site in M3 controls NMDAR single-channel conductance (g) and
voltage-dependent block by Mg2þ. (a) The characteristic high (w50 pS) conductance of
GluN1/GluN2A NMDARs is changed to a GluN1/GluN2D-like conduction by the point
mutation GluN2A(S632L). (b) The reciprocal mutation in GluN2D that replaces the
leucine residue at position 657 by serine gives rise to single-channel currents with
a GluN1/GluN2A-like conductance. (c) The IC50 values for voltage-dependent Mg2þ-
block for GluN1/GluN2A(S632L) are comparable to those for GluN1/GluN2D NMDARs
while IC50 values for GluN1/GluN2D(L657S) resemble those for GluN1/GluN2A
NMDARs. Panels (a)-(c) from Siegler Retchless et al. (2012). Copyright  2012 Nature
Publishing Group. Used with permission.
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1992; Sakurada et al., 1993; Wollmuth et al., 1998). Nevertheless
given the sequence identity between all GluN2 NMDAR subunits it
is clear that these residues themselves are not responsible for the
differences in the permeation properties that are seen between
GluN2A/B and GluN2C/D subunits. Studies using chimeric receptors
had identiﬁed regions within GluN2 subunits that controlled block
by Mg2þ and single-channel conductance (Kuner and Schoepfer,
1996; O’Leary and Wyllie, 2009) but the recent identiﬁcation of
a single amino acid residue that controls each of these three sig-
nature properties of NMDARs has somewhat simpliﬁed our un-
derstanding of NMDAR function (Siegler Retchless et al., 2012).
Near the intracellular side of the third membrane-associated
domain GluN2A/B subunits contain a conserved serine residue
(Ser632 in GluN2A) whereas the equivalent position in GluN2C/D
subunits contains a leucine residue (Leu657 in GluN2D). Fig. 3 il-
lustrates that the point mutation GluN2A(S632L) converts single-
channel conductance from GluN2A/B-like to GluN2C/D-like
(Fig. 3a) while the corresponding GluN2D(L657S) mutation con-
verts from GluN2C/D-like to GluN2A/B-like (Fig. 3b). Additionally
these pairs of point mutations also convert voltage-dependent
Mg2þ-block and Ca2þ permeability such that it now resembles
that seen for subunits normally containing either the serine or
leucine residue (Fig. 3c). Thus, while the intricate details of the
kinetic features of NMDAR function show considerable complexity
(discussed next) this ﬁnding elegantly demonstrates that there is
a single molecular determinant for these aspects of ion permeation
and block in NMDARs.
The slow deactivation of the NMDAR component of the gluta-
matergic EPSC is determined by the nature of the underlying in-
dividual channel activations which summate and give rise to the
macroscopic current while the variations in the time-course of
synaptic currents mediated by different NMDAR subtypes are
explained by the subtype-dependent differences in the durations
for which glutamate remains bound at its binding site. Heteroge-
neity of activations in single-channel data records are well docu-
mented and arise not only because of differences in NMDAR
subunit composition but also occur because both native and
recombinant NMDARs display modal gating where the activity of
a single receptor subtype switches between periods of high, me-
dium and low open probabilities (Amico-Ruvio and Popescu, 2010;
Borschel et al., 2012; Popescu and Auerbach, 2003; Popescu et al.,
2004; Zhang et al., 2008 and reviewed in Popescu (2012)). Modal
gating aside, it is the GluN2 composition of NMDARs that is the
main determinant of the nature and duration of single-channel
activations of NMDARs. Fig. 4 illustrates single-channel activity
for each of the four di-heteromeric GluN1-GluN2 NMDAR subtypes
recorded in the presence of saturating concentrations of glutamate
(and glycine) and highlights the differences in the behaviour of
NMDAR subtypes. GluN1/GluN2A NMDARs possess the highest
open probability (around 0.5) while for GluN1/GluN2B NMDARs
this parameter is about 3e5 fold lower. These values however are
considerably greater than the open probabilities for GluN1/GluN2C
and GluN1/GluN2D NMDARs (Amico-Ruvio and Popescu, 2010;
Banke and Traynelis, 2003; Chen et al., 1999; Dravid et al., 2008;
Erreger et al., 2005a; Popescu and Auerbach, 2003; Popescu et al.,
2004; Schorge et al., 2005; Vance et al., 2012; Wyllie et al., 1998;
Zhang et al., 2008). Indeed the open probability of GluN2C- and
GluN2D-containing NMDARs is exceptionally low (around 0.01e
0.04) indicating that even when fully liganded these channels
remain in closed states for the vast majority of their activations
(Dravid et al., 2008; Vance et al., 2012; Wyllie et al., 1998).
The single-channel records in Fig. 3 illustrate steady-state ac-
tivity of NMDARs, however synaptic activation of NMDARs occurs
under non-equilibriumconditions and therefore in terms of channelactivity we need to understand the nature of an individual channel
activation that begins with the ﬁrst opening following agonist
binding and endswith the last closing before dissociation of agonist,
as would occur during the synaptic release of glutamate. These in-
dividual activations or ‘bursts’ of activity, if correctly identiﬁed in
single-channel recordings, will predict the macroscopic response
(Colquhoun et al., 1997). For NMDARs it has long been recognised
that the nature of these bursts is exceedingly complex (Gibb and
Colquhoun, 1991, 1992; Howe et al., 1991) and contain multiple
open and closed states. As is predicted from studies of macroscopic
deactivation rates following brief applications of glutamate (Vicini
Fig. 4. The single-channel characteristics of NMDARs are determined by the GluN2
subunit assembled within the receptor. Steady-state single-channel recordings from
excised outside-out membrane patches isolated from HEK293 cells expressing either
GluN1/GluN2A, GluN1/GluN2B, GluN1/GluN2C, or GluN1/GluN2D NMDARs. For each
receptor combination the upper panel illustrates 20 s of activity while the lower panel
shows a selected higher resolution 100 ms period of activity. For all recordings,
channel activity was elicited by glutamate (1 mM) in the presence of glycine (0.05 mM)
and performed at pH 8.0 in 0.5 mM Ca2þ. Unpublished data, kindly provided by S. M.
Dravid, K. Erreger, K. Ogden, K. M. Vance, and S. F. Traynelis.
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shortest for GluN1/GluN2A NMDARs (30e50 ms) and longest for
GluN1/GluN2D NMDARs (2000e4000 ms).
While our level of understanding of these events is not as
complete as for example nicotinic acetylcholine receptors found at
the muscle endplate or inhibitory glycine receptors (Lape et al.,
2008; Sivilotti, 2010) kinetic schemes have been proposed for
each of the four di-heterometric NMDAR subtypes which describe
many of the subtype-speciﬁc features of individual activations and
accurately describe the time-course of deactivation following brief
pulses of agonist application (Amico-Ruvio and Popescu, 2010;
Banke and Traynelis, 2003; Dravid et al., 2008; Erreger et al., 2005a;
Popescu and Auerbach, 2003; Popescu et al., 2004; Schorge et al.,
2005; Vance et al., 2012; Zhang et al., 2008). Point mutations in
the GluN2 LBD that increase the rate at which glutamate dissociatesfrom its binding site cause shortening of channel activations and
concomitant increases in the rate with which macroscopic currents
deactivate following brief applications of agonist (Anson et al.,
1998, 2000; Chen et al., 2004). Fig. 5a illustrates the dramatic
shortening in GluN1/GluN2D burst lengths when a threonine res-
idue, located in S2 region, is mutated to alanine (Chen et al., 2004).
Similarly, agonists with different dissociation rates but acting at the
same NMDAR subtype give rise to individual channel activations
possessing different mean durations with appropriately altered
deactivation kinetics of macroscopic currents (Banke and Traynelis,
2003; Erreger et al., 2005b; Vance et al., 2011). Clearly the rate at
which glutamate (or any agonist) dissociates from its binding site
determines the duration of the activation. Nevertheless for each
GluN2 subunit the residues that H-bond with glutamate in the LBD
show few subunit differences (reviewed in Chen andWyllie (2006))
and of themselves, while being critically involved in contributing to
the rate at which dissociation occurs, do not account for the
NMDAR subtype-dependence of the duration of channel activations
(or the deactivation rates of macroscopic current responses). In this
respect two recent studies (Gielen et al., 2009; Yuan et al., 2009)
have identiﬁed the ATD and the short linker region between the
ATD and LBD, together with the LBD itself as structural elements
within GluN2 subunits that control NMDAR subtype channel open
probability, the duration of channel activations as well as agonist
potency (Fig. 5b). Additional regulation of the kinetic behaviours of
GluN1/GluN2B and GluN1/GluN2D NMDARs is provided by the
nature of the GluN1 splice variant present in the tetrameric re-
ceptor assembly (Fig. 5c) (Rumbaugh et al., 2000; Vance et al.,
2012). For both of these NMDAR subtypes the presence of exon 5
(the ‘b’ splice variants of GluN1 subunits) causes an increased rate
of current deactivation. Indeed if GluN1 ‘b’ splice variants pre-
dominate in NMDARs which are thought to be tri-heteromeric as-
semblies of GluN1 and either GluN2A or GluN2B together with
GluN2D (Brothwell et al., 2008; Harney et al., 2008; Logan et al.,
2007; Suarez et al., 2010) this may explain why they do not
exhibit the very slow decay time-course that is seen when GluN2D
subunits assemble with exon-5 lacking (‘a’ forms) of GluN1
(Monyer et al., 1994; Vicini et al., 1998; Wyllie et al., 1998; Yuan
et al., 2009).
4. GluN2-selective ligands: tools to identify native NMDARs
As discussed above each NMDAR subtype possesses a unique set
of biophysical characteristics that allow unambiguous identiﬁcation
of a particular di-heteromeric subunit combination. Nevertheless it
is not always possible or desirable to perform such a ‘ﬁngerprint’
analysis of NMDAR properties in order to determine the composi-
tion of a population of native NMDARs. Ideally one would want to
use ligands which either block or modify NMDAR function in
a subtype-selectivemanner and that would permit the dissection of
a native NMDAR population and an elucidation of the role(s) each
NMDAR subtype performs. The repertoire of NMDAR subtype-se-
lective antagonists and negative and positive allosteric modulators
has been extensively reviewed recently (Monaghan et al., 2012;
Ogden and Traynelis, 2011; Paoletti, 2011) and while advances have
been made in improving their selectivity there are still relatively
few ligands that exist which possess sufﬁcient potency and selec-
tivity to allow unambiguous identiﬁcation of NMDAR subtypes by
pharmacological methods alone. Furthermore, care needs to be
taken when working with systems in non-equilibrium conditions,
such as synaptic transmission, and comparing data obtained from
pharmacological characterisation of parameters that have been
determined in steady-state experiments.
For NMDARs comprised of GluN1 and GluN2B subunits the non-
competitive, negative allosteric modulators, ifenprodil (Williams,
Fig. 5. Control of NMDAR deactivation rates. (a) Example of a burst of openings arising from an activation of a wild-type (WT) GluN1/GluN2D NMDAR (ai. upper panel, grey); lower
three traces (black) show examples of single activations of GluN1/GluN2D(T692A) NMDARs. For each the line denotes the period between the ﬁrst opening and last closing of each
burst. Comparison of burst length distributions (aii) for GluN1/GluN2D(T692) and WT GluN1/GluN2D NMDARs (shown as a dashed grey line). Note the numbering used to indicate
the position of the threonine residue in GluN2D is for the mature protein (i.e. it excludes the signal peptide). (b) Representative whole-cell currents recorded from an HEK293 cell
expressing GluN1/GluN2D NMDARs (bi) or GluN1/GluN2D NMDARs in which the ATD was removed (bii). Note the increase in the deactivation rate when the GluN2D ATD is absent.
(c) Exon-5 lacking GluN1-1a subunits (ci) when co-expressed with GluN2D form NMDARs with typical slow deactivation rates, whereas GluN1-1b subunits which containing exon 5
(cii) accelerate deactivation of GluN2D-containing NMDARs. Panel (a) from Chen et al. (2004); (b) from Yuan et al. (2009) and (c) from Vance et al. (2012). Used with permission.
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1-piperidine propranol (Ro25-6981; Fischer et al., 1997) and
(1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-
propanol (CP-101,606; Mott et al., 1998) are exemplars of a wide
range of compounds (Mony et al., 2009) that display a selectivity for
this receptor combination of around 100-fold over other di-
heteromeric NMDAR combinations that allows these antagonists
to be used to probe effectively NMDAR subunit composition and
function in native neurons. The binding site for these antagonists is
located at the interface of the GluN1 and GluN2B ATDs (Karakas
et al., 2011) with the determinants of GluN2B susceptibility to
block by these antagonists being widely distributed. Indeed only
one residue differs between GluN2B (Ile111) and GluN2A (Met112)
at the phenylethanolamine binding site and mutation of the
GluN2Amethionine residue to isoleucine does not confer ifenprodil
sensitivity to GluN1/GluN2A NMDARs nor is it lost at GluN1/
GluN2B NMDARs if the isoleucine residue is replaced by methio-
nine (Karakas et al., 2011). A recent study (Burger et al., 2012) has
mapped extensively the residues at the GluN1-GluN2B ATD dimer
interface that control the potency of a large number of GluN2B-
selective negative allosteric modulators. Through site-directed
mutagenesis and molecular modelling this study demonstrated
that there are ligand-speciﬁc contacts within this binding for the
large number of compounds which act at this allosteric site. This, of
course, offers the potential for the further development of drugs
with greater potency or which possess less off-target binding.Nevertheless, given the overall near identical amino acid sequence
homology between GluN2A and GluN2B at this site, it remains to be
determined what structural elements control the very strong
subunit-speciﬁcity of ifenprodil and related ligands.
The quest for a similarly selective GluN1/GluN2A NMDAR an-
tagonists has been long and has been met with only limited suc-
cess. While initial reports suggested that (R)-[(S)-1-(4-bromo-
phenyl)-ethylamino]-(2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-
methyl]-phosphonic acid (NVP-AAM077) (Auberson et al., 2002)
showed 100-fold selectively for human GluN2A-containing
NMDARs over GluN2B-containing NMDARs these were later
shown not to hold for rodent NMDARs where the difference in
KB values for NVP-AAM077 acting at the two NMDAR subtypes
showed only a 5-fold difference (Frizelle et al., 2006). Residues in
the LBD of human and rodent GluN2A and GluN2B subunits differ
by only two amino acids between species, neither of which
are direct contact residues within the glutamate binding site,
and no major differences have been found in other studies that
have directly compared other agonist and antagonist potencies at
rodent and human NMDARs (Hedegaard et al., 2012; Otton et al.,
2011). Indeed the lack of selectively of this antagonist acting at
rodent NMDARs was highlighted early on in a study exam-
ining synaptic function in GluN2A-lacking mice (Berberich et al.,
2005) where NVP-AAM077 at concentrations used to produce
what was considered to be selective block of GluN2A-containing
NMDARs caused a 60% block of remaining (GluN2B-mediated)
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to be widely used in many studies of NMDAR function and at
concentrations where it simply does not discriminate between
GluN2A- and GluN2B-containing NMDARs. Furthermore, compli-
cations arise when using potent competitive antagonists (such as
NVP-AAM077) under non-steady-state conditions as occurs dur-
ing the process of synaptic transmission. For example, consider an
experiment where an antagonist is pre-applied and equilibrium is
allowed to be established with the receptor population under
investigation. The duration of time available for agonist (neuro-
transmitter) binding during processes such as synaptic trans-
mission is typically in the order of 1e2 ms and not sufﬁcient for
a new receptor/agonist/antagonist equilibrium to be established.
Moreover, the lifetime of the receptoreantagonist complexes will
outlast considerably the duration that agonist is available for
binding and in effect an antagonist that under equilibrium condi-
tions is reversible now behaves in, effectively, an irreversible
manner (Wyllie and Chen, 2007). In other words, under the
non-stationary kinetics of synaptic transmission the observed po-
tency of the competitive antagonist is increased compared to
that determined in an experiment carried out under steady-state
conditions and therefore one can easily be misled when compar-
ing the magnitude of antagonism under conditions which are not
equivalent.
Recently, however, novel GluN2A-selective inhibitors have been
identiﬁed (Bettini et al., 2010) which show strong selectivity for
GluN1/GluN2A NMDARs over GluN1/GluN2B NMDARs. TCN 201 (3-
chloro-4-ﬂuoro-N-[4-[[2-(phenylcarbonyl)hydrazino]carbonyl]ben-
zyl]benzenesulphonamide) and TCN 213 (N-(cyclohexylmethyl)-2-
([4-thiadiazol-2-yl]thio)acetamide) each antagonise GluN1/GluN2A
NMDAR-mediated currents in a non-competitive but glycine-
dependent manner (Edman et al., 2012; Hansen et al., 2012; McKay
et al., 2012). In addition, both TCN 201 and TCN 213 block NMDAR-
mediated responses in neurones at a developmental time-point
where GluN2A subunits are known to be expressed or whereFig. 6. Antagonism of NMDAR-mediated currents by TCN 201. (a) Left, example steady-state
days in vitro (DIV) 9e10 neurones, (aii), DIV 9e10 neurones transfected with GluN2A NMDAR
each of these NMDAR-mediated currents to the GluN2B-selective antagonist, ifenprodil and t
201. (b) Plot illustrating the extent of ifenprodil and TCN 201 antagonism of NMDA-evoked
TCN 201 the data show a strong (negative) correlation. (c) Equivalent plot to that illustrated i
(2012) and (c) from McKay et al. (2012). Used with permission.neurones have been transfected to over-express GluN2A-containing
NMDARs (Edman et al., 2012;McKayet al., 2012) (Fig. 6). The site and
mechanism of action of TCN 201 has been examined in detail
(Hansen et al., 2012) and it is thought that TCN 201 acts as a negative
allosteric modulator of glycine binding by accelerating its dis-
sociation rate. Mutation of residues at the GluN1-GluN2A interface
(Leu777, Leu780 and Val783 in GluN2A and Phe754 and Arg755 in
GluN1) alters TCN 201 potency and highlight that this interface
harbours a novel site for allosteric modulation of NMDARs. Never-
theless, the glycine-dependency of the antagonism afforded by an-
tagonists such as TCN 201 and TCN 213 needs to be taken into
account during experimental design. The limited solubility of TCN
201 (themorepotentof the twoantagonists)means that in situations
where glycine (or D-serine) is used at a concentration of 30 mM (to
ensure saturation at the GluN1 co-agonist binding site) complete
inhibition of a GluN1/GluN2ANMDAR-mediated cannot be achieved
(Edman et al., 2012; Hansen et al., 2012; McKay et al., 2012). Fur-
thermore, care needs to be taken to determine the levels of glycine
(or D-serine) in experimental preparations so that the expected level
of inhibition of GluN1/GluN2A NMDAR-mediated responses can be
predicted e this is not always possible in, for example, in vitro slice
preparations. In addition it should be remembered that many for-
mulations of culture media contain high concentrations of glycine
that are considered to be saturating with respect to the NMDAR
glycine binding site and therefore the TCN compounds are rendered
ineffective under such conditions. Despite these caveats, non-
competitive glycine-site negative allosteric modulators such as
TCN 201 do not suffer from the same equilibrium/non-equilibrium
issues that are highlighted above when using potent competitive
glutamate-site antagonists if it is assumed that steady-state condi-
tions are achieved prior to the synaptic glutamate release. The dis-
covery of a novel allosteric binding site in GluN1/GluN2A NMDARs
raises the potential for future development of more potent ligands
that possess better solubility to allow for the selective and complete
block of GluN2A-containing NMDARs.whole-cell NMDAR-mediated currents recorded from cortical pyramidal cells from (ai),
subunits, and (aiii), DIV 15e18 neurones. To the right, traces illustrate the sensitivity of
he subsequent sensitivity of the ifenprodil-insensitive component of this current to TCN
currents. Despite a wide range in the amount of block produced by either ifenprodil or
n (b) but for antagonism by ifenprodil and TCN 213. Panels (a) and (b) from Edman et al.
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and GluN1/GluN2B diheteromeric NMDAR subtypes several novel
compounds have been described which selectively inhibit or
potentiate NMDARs containing GluN2C or GluN2D subunits.
(2R*,3S*)-1-(phenanthrene-3-carbonyl)piperazine-2,3-dicarboxylic
acid (UBP141; Morley et al., 2005) shows around 5e10 fold selec-
tively for GluN1/GluN2C or GluN1/GluN2D NMDARs over those
containing GluN2A or GluN2B subunits as determined by Schild
analysis (Costa et al., 2009). Nevertheless the selectivity of UBP141 is
not high and similar issues, to those mentioned above, arise when
using such ligands to determine the composition of synaptically
located NMDARs containing GluN2C or GluN2D subunits. In this
regard the recent discovery of both negative and positive allosteric
modulators that act at NMDARs containing GluN2C or GluN2D
subunits indicates that as is the case for TCN 201 acting at GluN1/
GluN2A NMDARs and ifenprodil acting at GluN1/GluN2B NMDARs
that sites out with the glutamate binding site itself offer the best
possibility for the selective inhibition (or potentiation) of speciﬁc
NMDAR subtypes. (E)-4-(6-methoxy-2-(3-nitrostyryl)-4-oxoquina-
zolin-3(4H)-yl)-benzoic acid (QNZ46; Hansen and Traynelis, 2011;
Mosley et al., 2010) is a non-competitive antagonist with approx-
imately 50-fold selectivity for GluN2C- and GluN2D-containing
NMDARs. Since it requires glutamate binding to the GluN2 subunit
(although not glycine binding to GluN1) its blocking action displays
use-dependency (Hansen and Traynelis, 2011). Residues which
control inhibition byQNZ46are located in the S2 regionof theGluN2
LBD and it is proposed that glutamate occupancy at its binding site
either allows accessibility of QNZ46 to its binding site or increases
the afﬁnity of the site for QNZ46. 4-(5-(4-bromophenyl)-3-
(6-methyl-2-oxo-4-phenyl-1,2-dihydroquinolin-3-yl)-4,5-dihydro-
1H-pyrazol-1-yl)-4-oxobutanoic acid (DQP-1105) although struc-
turally unrelated to QNZ46 is also thought to act at this site (Acker
et al., 2011). Selective potentiation of GluN2C- and GluN2D-
containing NMDARs can be achieved with 3-(chlorophenyl)(6,7-
dimethoxy-1-((4-methoxyphenoxy)methyl)-3,4-dihydroiso-quino-
lin-2(1H)-yl)methanone (CIQ; Mullasseril et al., 2010). In GluN2D
a residue in M1 (Thr592) has been identiﬁed, potentially, as the site
that controls CIQ activity. This residue is conserved in GluN2C but
not in either GluN2A or GluN2B subunits. Furthermore, CIQ poten-
tiates NMDAR-mediated currents in neurons from sub-thalamic
nuclei (Mullasseril et al., 2010), one of the few brain regions where
GluN2D expression is high (Standaert et al., 1994) and which
together with neurones from other components of the basal ganglia
have been shown to express functional NMDARs containing GluN2D
subunits (Brothwell et al., 2008; Jones and Gibb, 2005; Logan et al.,
2007; Suarez et al., 2010).
5. Tri-heteromeric NMDARs complicate pharmacological
studies
The characterisation of the speciﬁcity of ligands that block or
modify function is, almost always, carried out on recombinantly
expressed di-heteromeric NMDARs and then this information is
used to probe NMDAR properties in neuronal populations. How-
ever, complications arise since native populations are mixed and
will be comprised of both di- and tri-heteromeric combinations of
GluN1 and GluN2 subunits. Indeed it is considered that in the adult
forebrain that a substantial proportion of NMDARs contain together
with GluN1 both GluN2A and GluN2B subunits (Chazot and
Stephenson, 1997; Rauner and Kohr, 2011). The unique pharmaco-
logical properties of tri-heteromeric NMDARs was elegantly dem-
onstrated when it was shown that Zn2þ ions and ifenprodil
antagonise GluN1/GluN2A/GluN2B NMDARs to a lesser extent than
is seen at di-heteromeric GluN1/GluN2A or GluN1/GluN2B
NMDARs, respectively (Hatton and Paoletti, 2005). Similarly inearly post-natal development an equivalent level of inhibition is
observed for NMDAR-mediated currents in forebrain neurones
indicative of a predominant GluN1/GluN2B composition of native
NMDARs (Brothwell et al., 2008; Carmignoto and Vicini, 1992; Crair
and Malenka, 1995; Edman et al., 2012; Flint et al., 1997; Gray et al.,
2011; Hestrin, 1992; McKay et al., 2012; Rauner and Kohr, 2011;
Sheng et al., 1994; Stocca and Vicini, 1998). At later developmental
stages block by ifenprodil, Ro25-6981, CP-101,606 and related
allosteric inhibitors decreases, consistent with the increased
expression of GluN2A subunits and the presence of a substantial
population of native GluN1/GluN2A/GluN2B NMDARs (see for
example Edman et al. (2012), Gray et al. (2011), McKay et al. (2012),
Rauner and Kohr (2011)). It is also pertinent to note that the
presence of extracellular Mg2þ decreases the extent of block pro-
duced by ifenprodil and CP-101,606 at what are presumed to be
native tri-heteromeric GluN1/GluN2A/GluN2B NMDARs (Rauner
and Kohr, 2011). This effect of Mg2þ is not seen at recombinantly
expressed NMDARs nor at native NMDARs composed of predomi-
nantly only GluN1 and GluN2B subunits and serves as a reminder
that the presence of physiological concentrations of extracellular
Mg2þ can signiﬁcantly affect the pharmacological proﬁle of these,
together with other commonly used NMDAR antagonists (for
example see Kotermanski and Johnson (2009), Otton et al. (2011)).
While we have a good appreciation of the extent of antagonism
produced by ifenprodil and related compounds at tri-heteromeric
GluN1/GluN2A/GluN2B NMDARs (Hatton and Paoletti, 2005;
Rauner and Kohr, 2011) we have a much poorer knowledge of the
potency of other antagonists (or potentiators) acting at these or
other combinations of tri-heteromeric NMDARs. We do not know,
for example, whether the afﬁnity of an antagonist acting at a di-
heteromeric GluN1/GluN2 NMDAR is the same when the equiv-
alent GluN2 subunit in now present in a tri-heteromeric complex.
While this is possible to test in theory, the difﬁculty is not with the
study of the antagonism per se but rather in our ability to generate
NMDARs with known subunit combinations. For example, recom-
binant expression of GluN1 together with two GluN2 subtypes will
generate three distinct NMDAR populations. While it is possible to
detect using electrophysiological recordings functional NMDARs
containing two types of GluN2 subunits (Chefﬁngs and Colquhoun,
2000) controlling the reproducibility of the proportion with which
they are expressed with di-heteromeric receptors is more prob-
lematic. Assessment of the pharmacological proﬁle of agonists and
antagonists, together with the wide range of negative and positive
allosteric modulators that are now being identiﬁed, at tri-
heteromeric NMDARs while challenging, seems to be of critical
importance in order to further our appreciation of the functional
roles played by NMDAR subtypes.
6. Pharmacological investigations into GluN2 subtype-
speciﬁc plasticity
It is now 30 years since the demonstration of the requirement
for NMDAR activation for the induction of CA3-CA1 hippocampal
long-term potentiation (LTP; Collingridge et al., 1983) but an on-
going focus of considerable interest surrounds the possibility that
GluN2 subtypes contribute differentially to synaptic plasticity.
Pharmacological tools showing subunit-selectivity are in theory
ideal to test hypotheses centred on this area. Early studies
employed GluN2B-selective antagonists to show that GluN2B-
containing NMDARs were important for the induction of hippo-
campal and perirhinal long-term depression (LTD) respectively but
were not essential for LTP (Liu et al., 2004; Massey et al., 2004).
Their additional conclusions that GluN2A-containing NMDARs
were alone critical for the induction of LTP have since been tem-
pered somewhat in the light of the relative non-selectivity of NVP-
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both subunits can contribute to LTP.
For example, Winder and co-workers showed that NMDAR-
dependent hippocampal CA3-CA1 LTP induced by high frequency
stimulation did not have an absolute requirement for GluN2A-
containing NMDARs, as evidenced by studying GluN2A-deﬁcient
slices (Weitlauf et al., 2005). Moreover, they showed that the con-
centration of the GluN2A-preferring drug NVP-AAM077 (400 nM)
used previously to implicate GluN2A-containing NMDARs (Liu
et al., 2004) was not selective since it even blocked LTP in
GluN2A-deﬁcient slices. The careful use and characterization of
low-dose NVP NVP-AAM077 as a GluN2A-preferring antagonist, in
combination with GluN2B-selective antagonists also supported
a role for both GluN2A and GluN2B in mediating LTP (Bartlett et al.,
2007). However, similar studies have concluded that LTP is pref-
erentially induced by GluN2A-containing NMDARs (Moult and
Harvey, 2011). Interestingly, Kohr and co-workers used both low-
dose GluN2B and GluN2A-preferring antagonists, and genetic loss
of GluN2A to conclude that, at least in the case of low frequency
stimulation protocols (paired with post-synaptic depolarization)
that both GluN2A and GluN2B-containing NMDARs contributed to
LTP and that charge transfer/Ca2þ inﬂuxwas themajor determining
factor rather than participation of any particular subtype (Berberich
et al., 2007, 2005). Related to this is the recent observation that at
amygdala synapses LTP is mediated via GluN1/GluN2A/GluN2B tri-
heteromeric NMDARs (Delaney et al., 2012).
In addition to there being impaired LTP in the GluN2A knockout
mouse (Sakimura et al., 1995), genetic evidence also now points to
a role for GluN2B: analysis of a mouse containing a forebrain-
speciﬁc deletion of GluN2B revealed a deﬁcit in paired protocol
CA3-CA1 LTP attributable to reduced charge transfer (von
Engelhardt et al., 2008). In contrast, ﬁeld LTP remained unaltered,
perhaps reﬂecting a stronger stimulation that could elicit sufﬁcient
NMDAR-dependent Ca2þ inﬂux even through the GluN2B-deﬁcient
synapses (von Engelhardt et al., 2008). Thus, a tentative consensus
is emerging that both GluN2A and GluN2B-containing NMDARs can
both contribute to LTP in relatively mature hippocampal slices.
However, interpretation of pharmacological experiments is clou-
ded a little by the fact that, as noted above, tri-heteromeric
NMDARs containing GluN2A and GluN2B contribute a substantial
amount to synaptic NMDAR currents at the CA1 synapse. Moreover,
as indicated above, the effect of NVP-AAM077 on these channels,
alone or in combination with GluN2B-preferring antagonists (as
employed in many studies) is not clear. Also, as noted above,
GluN2B-preferring antagonists have limited effects at GluN1/
GluN2A/GluN2B triheteromeric receptors, meaning that just
because LTP is not blocked by a GluN2B-preferring antagonist, this
does not mean that GluN2B is not needed for LTP (it may be playing
a critical role as part of GluN1/GluN2A/GluN2B triheteromeric re-
ceptors). Also, as noted above, the dose-dependent potency and
dose-dependent subunit-selectivity of NVP-AAM077 under non-
steady-state conditions of synaptic transmission are less than clear.
These issues should be borne in mind when interpreting in-
vestigations into GluN2 subtype-speciﬁc function based purely on
pharmacological tools.
7. Use of chimeric GluN2 subunits to probe subunit-speciﬁc
function
Mammalian GluN2 subunits have large cytoplasmic C-terminal
domains (CTDs) that are responsible, along with the CTD of GluN1,
for linking the NMDAR to an array of signalling and scaffolding
proteins that together form the NMDAR signalling complex (Husi
et al., 2000; Kim and Sheng, 2004; Ryan et al., 2008). The amino
acid sequences of the different GluN2 subunit CTDs have divergedsubstantially during evolution, and have the potential to differ-
entially link to signalling molecules (Ryan et al., 2008). This led to
the hypothesis that in addition to the GluN2 subtype conferring
speciﬁc biophysical properties on the NMDAR, the GluN2 CTD
subtype may additionally provide functional diversity by inﬂu-
encing downstream effectors of NMDAR activation. This has been
investigated recently in the context of synaptogenesis, synaptic
plasticity, excitotoxicity, and behaviour and cognition, with a focus
on differential effects of the CTDs of GluN2A and GluN2B, the adult
major forebrain GluN2s.
An important requisite of such studies is to uncouple any in-
ﬂuence of the channel/ligand-binding portion of the GluN2 subunit
from that of the C-terminus. An approach taken by several labs has
been to investigate the functional consequences of the expression
of both wild-type GluN2A and GluN2B compared to expression of
chimeric GluN2 subunits in which the CTD of one subunit has been
switched with that of the other. By studying, for example, the
consequence of GluN2B expression compared with that of
expressing GluN2B with its CTD replaced with that of GluN2A (and
vice-versa), the effects of the CTD subtype can be investigated in
isolation. These approaches are valid because there is no evidence
that swapping the GluN2 CTD subtype would inﬂuence the gating
properties of the NMDAR. Indeed, this possibility has now been
directly tested and ruled out (Maki et al., 2012; Punnakkal et al.,
2012).
Using this approach Sheng and co-workers demonstrated an
important role for the GluN2B CTD in hippocampal LTP: knock-
down of GluN2B inhibited LTP and could be rescued by expression
of a RNAi-resistant form of GluN2B but not by GluN2A or by GluNB
with its CTD replaced by that of GluN2A (Foster et al., 2010). Con-
ceptually similar approaches were employed by Gambrill and Bar-
ria to investigate GluN2 subtype-speciﬁc synaptogenesis and
stabilization (Gambrill and Barria, 2011). Premature GluN2A over-
expression resulted in lowered spine density and miniature EPSC
frequency in the hippocampus, indicative of restricted synapto-
genesis. The effect could be recapitulated by over-expressing
GluN2B with the CTD of GluN2A, but not by wild-type GluN2B
nor by GluN2A with the CTD of GluN2B, thus implicating the
GluN2A CTD speciﬁcally in this phenomenon. Further experiments
implicated the reported inability of CaMKII to interact with the
GluN2A CTD as being responsible for this, suggestive of a speciﬁc
role for the GluN2B CTD in normal synaptic development.
Grant, Komiyama and co-workers recently used an alternative,
and elegant, approach which enabled them to study the role of
GluN2 CTD subtype in the whole animal (Ryan et al., 2013). Rather
than ectopically expressing chimeric GluN2 subunits, they made
two knock-in mice by targeted exon exchange: one in which the
CTD of GluN2B was replaced with that of GluN2A, and one inwhich
the CTD of GluN2A was replaced with that of GluN2B. Strikingly,
analysis of a battery of learnt and innate behaviours in these mice
revealed differing requirements for the two GluN2 CTDs. Some
tasks were insensitive to either replacement of the CTD of GluN2A
(with that or GluN2B) or the replacement of the CTD of GluN2B
(with that of GluN2A). In contrast, several tasks had an absolute
requirement for the CTD of GluN2B only, one task had an absolute
requirement of the CTD of GluN2A, and one appeared to require the
presence of both CTDs. Parallel investigations were also performed
aimed at investigating the role of GluN2 CTD subtype in hippo-
campal synaptic plasticity. Using both theta-burst and theta-pulse
induction of LTP it was shown that the GluN2A CTD could be
swapped for that of GluN2B without inﬂuencing plasticity. In
contrast, exchange of the CTD of GluN2B for that of GluN2A
enhanced theta-burst LTP but suppressed theta-pulse LTP. This
places the GluN2B CTD as being important for decoding speciﬁc
patterns of electrical activity in a manner that cannot be achieved
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CTD of GluN2A exhibited far lower levels of interaction between
GluN2B and the MAGUK proteins PSD-95 and PSD-93, suggesting
that the GluN2B CTD may link to a qualitatively or quantitatively
different protein complex in the forebrain. In potential support of
this idea is the recent observation that GluN2A-containing
NMDARs induce LTP via a mechanism dependent on Ras-GRF2,
while GluN2B-containing NMDARs induce LTP independent of
this pathway (Jin and Feig, 2010). Collectively these data support
the notion that ancestral duplication of the GluN2 gene has enabled
sequence divergence, leading to increased diversity in synaptic
signalling, potentially underlying the capacity for an enhanced
repertoire of complex behaviours (Ryan et al., 2013).
We recently addressed the role of GluN2 CTD subtype in
determining NMDAR excitotoxicity (Martel et al., 2012). Ectopic
expression of chimeric GluN2A and 2B subunits with reciprocal
exchanges of their CTDs showed that compared to the CTD of
GluN2A that of GluN2B more efﬁciently coupled NMDAR-
dependent Ca2þ inﬂux to neuronal death. Indeed, this was
observed regardless of whether the GluN2B was attached to the
rest of the GluN2B subunit, or as part of a chimeric subunit linked to
GluN2A. In collaboration with Grant and Komiyama we studied
excitotoxicity in vitro and in vivo utilizing their mouse expressing
GluN2B with its CTD replaced with that of GluN2A. In exact
agreement with our ectopic expression studies, replacing GluN2B’s
CTD with that of GluN2A reduced neuronal sensitivity to NMDAR-
dependent Ca2þ inﬂux both in vitro culture and in vivo following
an excitotoxic insult (Fig. 7). The molecular basis for this GluN2 CTDFig. 7. The identity of the GluN2 CTD determines the response to excitotoxic insult. (a) Carto
from GluN2A and denoted as GluN2B2A(CTR). (b) Quantiﬁcation of hippocampal lesion volu
NMDA into the hippocampi of either GluN2Bþ/þ or GluN2B2A(CTR)/2A(CTR) mice. Note the signi
(c) Upper panels, representative pictures of haematoxylin and eosin-stained hippocampal
higher magniﬁcation of the boxed areas shown in the upper panels. Calibration bars in uppe
et al. (2012). Copyright  2012 Cell Press. Used with permission.subtype-speciﬁc effect was an increased physical and functional
coupling of the GluN2B CTD to a PSD-95-nNOS-dependent CREB
dephosphorylation pro-death pathway, although contributions
from other CTD subtype-speciﬁc pathways are likely to exist and
await further investigation. It should be noted that not all GluN2B-
mediated signalling is bad though e activation of synaptic GluN2B-
containing NMDARs promoted by physiological action potential
bursting is potently neuroprotective (Al-Mubarak et al., 2009;
Martel et al., 2009b; Papadia et al., 2008). The toxic consequences of
GluN2B CTD signalling are only observed in the context of chronic
activation of all (synaptic and extrasynaptic NMDARs) by elevated
ambient levels of agonist (Martel et al., 2009b). Under these con-
ditions the chronic, tonic activation of NMDARs, particularly
extrasynaptic NMDARs leads to very different downstream effects
in terms of signalling cascades (Hardingham and Bading, 2002;
Ivanov et al., 2006; Leveille et al., 2008; Papadia et al., 2008) and
transcriptional outputs (Hardingham and Bading, 2002; Soriano
et al., 2009; Wahl et al., 2009; Zhang et al., 2007) with delete-
rious consequences (for a comprehensive review on this topic see
Hardingham and Bading (2010)).
It will also be important to determine whether GluN2 CTD
subtype determines the progression or severity of neurological
conditions associated with abnormal or inappropriate NMDAR
function, such as ischaemia, traumatic brain injury or chronic pro-
gressive disorders such as Huntington’s disease. Neuroprotective
peptide mimetics of the GluNB CTD and downstream interacting
proteins are an emerging area of interest, with several showing
promise in rodent stroke models (Aarts et al., 2002; Bach et al.,on depiction illustrating the C-terminal replacement (CTR) of the GluN2B CTD with that
mes 24 h after stereotaxic injection of phosphate buffered saline (PBS) or 15 nmol of
ﬁcant reduction in lesion volumes when the GluN2B CTD is replaced by that of GluN2A.
sections showing the extent of NMDA-induced damage (dashed lines); lower panels,
r and lower panels are 250 mm and 50 mm, respectively. Panels (b) and (c) from Martel
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peptide mimetic of the GluN2B PDZ ligand (NA-1, Tat-NR2B9c
(Aarts et al., 2002)). This peptide was found to partly uncouple
GluN2B-containing NMDARs from PSD95, reducing NO production
following excitotoxic insult and suppressing pro-death p38 signal-
ling and CREB shut-off (Aarts et al., 2002;Martel et al., 2012; Soriano
et al., 2008). Also, unlike conventional NMDAR antagonists, NA-1/
Tat-NR2B9c did not interfere with activity-dependent synaptic
potentiation, nor synaptic NMDAR-dependent neuroprotective sig-
nalling via Akt or CREB (Martel et al., 2009a; Soriano et al., 2008).
Moreover NA-1/Tat-NR2B9c was shown to be effective post-
treatment in reducing lesion size and improving outcome follow-
ing stroke in the non-human primate brain (Cook et al., 2012). NA-1
has also advanced to human clinical trials for iatrogenic stroke after
endovascular aneurysm repair (Hill et al., 2012). Phase 2 results
published very recently revealed no adverse side effects to NA-1,
and a signiﬁcant reduction in the number of ischemic infarcts
compared to placebo (Hill et al., 2012). To conclude, the idea that
GluN2B CTD-speciﬁc signalling underlies neuronal dysfunction and
death in a variety of neurological conditions is an attractive one,
and although the role of the GluN2B CTD in plasticity and behaviour
is becoming clear, recent work has shown that it is nevertheless
realistic to hope that targeting the CTD will give far less severe side
effects than global antagonists.
8. Conclusions
In this reviewwe have focussed on the role played by the GluN2
subunit in controlling NMDAR function. These subunits are critical
determinants of NMDAR heterogeneity and provide the major in-
ﬂuence in determining NMDAR subtype biophysical, pharmaco-
logical and signalling properties. In recent years our rapidly
advancing understanding of NMDARs has allowed for the identiﬁ-
cation of structural elements and, at times, single amino acid res-
idues, which determine GluN2-speciﬁc control of function. This
understanding provides us with opportunities to develop novel
pharmacological agents with which we can probe NMDAR subtype-
speciﬁc physiological and pathophysiological functions, the ulti-
mate aim of which is the treatment of neurological dysfunction.
Indeed, as indicated in the ﬁnal section of the review selective
targeting of GluN2-dependent function shows such strategies
possess considerable clinical promise.
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